Work

Targeting the T-Cell Co-stimulatory CD27/CD70 Pathway in Cancer Immunotherapy: Rationale and Potential

Year: 2015
Type: review
Abstract: In 2013, cancer immunotherapy was named 'breakthrough of the year' based on the outcome of clinical trials with blocking antibodies to the T-cell co-inhibitory receptors CTLA-4 and PD-1. This success has emphasized that cytotoxic T-cell responses to cancer can occur, but are limited by peripheral tolerance and by immunosuppression in the tumor microenvironment. Targeting of CTLA-4, PD-1 or its ligands partly overcomes these limitations and can now be applied in multiple immunogenic cancer types. Furthermore, an increased success rate is expected from combining CTLA-4 and/or PD-1 blocking with deliberate engagement of T-cell co-stimulatory receptors, particularly TNF receptor (R) family members. The TNFR family includes CD27 (Tnfrsf7), for which an agonistic antibody has recently entered clinical trials. In this review, we describe how CD27 co-stimulation impacts the T-cell response, with the purpose to illuminate how CD27 agonism can be exploited in cancer immunotherapy.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Award: G756973485
OpenAlex ID: W2161261138
FWCI: 1.369
Cites: 84
Cited by: 204
Related to: 10